glp 1 coverage 2025 Employer Approaches to GLP-1 CVS reports 50% of clients

Meg Tirrell 00:28:43 I hope we have a lot more information about what these drugs are doing

Healthcare professionals must carefully weigh potential benefits against risks, ensure appropriate monitoring, and maintain realistic expectations about outcomes

de la Pena A, Cui X, Geiser J, Loghin C

If anything, pressure is only intensifying as Novo and Lilly continue to jockey for dominance, and as new challengers look to tap into this burgeoning market

Sharon Fruh: Served on advisory board for Novo Nordisk

Some of his patients go further and extract precise smaller doses of tirzepatide from the pen using an insulin syringe a technique that Garg does not recommend